Semaglutide as adjunctive therapy to catheter ablation in obesity-related paroxysmal atrial fibrillation - PubMed
3 months ago
- #obesity
- #semaglutide
- #atrial-fibrillation
- Semaglutide, a GLP-1 receptor agonist, was studied as adjunctive therapy to catheter ablation in obese patients with paroxysmal atrial fibrillation (AF).
- The study compared 181 semaglutide-treated patients with 181 matched controls who did not receive GLP-1RA therapy.
- At 18-month follow-up, semaglutide-treated patients had a significantly lower risk of AF recurrence (80.2% vs. 65.2% freedom from recurrence).
- Semaglutide led to significant weight loss (-11.8±3.8 kg) and BMI reduction (-4.0±1.4 kg/m²) compared to minimal changes in controls.
- A substantial proportion of semaglutide-treated patients achieved ≥10% weight reduction.
- The study suggests semaglutide may reduce AF recurrence post-ablation in obese patients, indicating its potential as an adjunctive treatment.